

Datasheet for 600-401-FM2**TOSO Antibody****Overview**

Description:	Anti-Toso (RABBIT) Antibody - 600-401-FM2
Item No.:	600-401-FM2
Size:	100 µg
Applications:	ELISA, WB
Reactivity:	Human
Host Species:	Rabbit

Product Details

Background:	Apoptosis is an important process by which normal tissue homeostasis and function are maintained. One of the major signals that regulate this process is mediated by the activation of the Fas receptor by its ligand. This leads to the formation of a Fas-associated death domain (FADD)- containing death-inducing signaling complex and the activation of caspase-8, which in turn activates downstream effector caspases, such as caspase-3 and -7. Recent experiments have shown that overexpression of Toso, a novel regulator of Fas-induced apoptosis in lymphoid cells, in Jurkat cells as well as transgenic mice render these cells resistant to Fas-induced apoptosis but not to TRAIL-induced apoptosis. Furthermore, Toso was found to associate with FADD, suggesting that Toso functions by disrupting the formation of the death-inducing signaling complex.
Synonyms:	Toso Antibody, FCMR, TOSO, Fas apoptotic inhibitory molecule 3, Regulator of Fas-induced apoptosis Toso, IgM Fc fragment receptor, FAIM3
Host Species:	Rabbit
Clonality:	Polyclonal
Format:	IgG

Target Details

Gene Name:	FCMR
Reactivity:	Human
Immunogen Type:	Conjugated Peptide

Immunogen:	Anti-Toso antibody was prepared from whole rabbit serum produced by repeated immunizations with a 13 amino acid synthetic peptide from near the C-terminus of human Toso.
Purity/Specificity:	Anti-Toso Antibody was affinity purified from monospecific antiserum by immunoaffinity chromatography. Cross reactivity with Toso from other sources has not been determined.
Relevant Links:	• UniProtKB - O60667 • GeneID - 9214 • NCBI - NP_001135945.1

Application Details

Tested Applications:	ELISA, WB
Application Note:	Anti-Toso Antibody has been tested for use in ELISA and Western Blotting. Specific conditions for reactivity should be optimized by the end user. Expect a band at approximately 43 kDa in Western Blots of specific cell lysates and tissues.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	1:10,000
WB:	1 µg/mL


Formulation

Physical State:	Liquid (sterile filtered)
Concentration:	1 mg/mL by UV absorbance at 280 nm
Buffer:	0.01 M Sodium Phosphate, 0.25 M Sodium Chloride, pH 7.2
Preservative:	0.02% (w/v) Sodium Azide
Stabilizer:	None

Shipping & Handling

Shipping Condition:	Dry Ice
Storage Condition:	Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration:	Expiration date is one (1) year from date of receipt.

Images



Western Blot

Western Blot of Toso antibody. Lane 1: Human lung tissue.

Lane 2: Human lung tissue in the presence of blocking peptide. Load: 35 µg per lane. Primary antibody: Toso

antibody at 1 µg/mL for overnight at 4°C. Secondary

antibody: Peroxidase rabbit secondary antibody at 1:10,000 for 45 min at RT. Block: 5% BLOTTO overnight at 4°C.

Predicted/Observed size: 43.1 kDa, 63 kDa for Toso.

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin.

Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.